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Abstract
Identification of Fabry disease (FD) in cardiac patients has been restricted so far to patients with left ventricular
hypertrophy. Conduction problems are frequent in FD and could precede other manifestations, offering a possible
earlier diagnosis.
We studied the prevalence of FD in 188 patients < 70 years with conduction problems requiring pacemaker
implantation. Although classical manifestations of FD were not rare, no patient with FD was identified. Screening
efforts should not be conducted in this population.
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Anderson-Fabry disease (AFD) is a rare condition associ-
ated with an important diagnostic delay [1]. Contribut-
ing factors are the rarity of this disease and the lack of
awareness among physicians. Early diagnosis is import-
ant in AFD because appropriate therapies seem to be
more effective when initiated promptly.
AFD is an X-linked disordersecondary to mutations in
the GLA gene, resulting in a deficiency in α-
galactosidase A (α-Gal A), which leads to the abnormal
accumulation of globotriaosylceramide in affected or-
gans. At the cardiac level, patients with AFD can present
with hypertrophic cardiomyopathy, microvascular angina
and conduction problems/arrhythmias [2].
Efforts in the identification of AFD in cardiac patients
have been restricted to screening of large series of patients
with unexplained left ventricular hypertrophy, where AFD
has been reported in 1–2% of individuals [3].
Although AFD patients mostly die because of cardiac
problems, unexplained left ventricular hypertrophy is
present in only one-half of all AFD patients. Moreover,
conduction problems and arrhythmias are a frequent
problem in patients with AFD and could precede other
cardiac manifestations, offering a possible earlier diagno-
sis. Indeed, the rate of pacemaker insertion (PMI) in
AFD has been described to be 25 times higher than
in the general population, and the requirement of PMI
has been reported to be as high as 8% in some AFD
series [4, 5].
With these data, we hypothesized that AFD could be
an underdiagnosed entity among patients with unex-
plained conduction disturbances requiring PMI, and that
this group of patients could be an appropriate group to
test screening strategies.
We therefore designed a multicenter, cross-sectional
study to investigate the prevalence of AFD in patients
with unexplained atrioventricular blockade or sinus node
disease requiring PMI at < 70 years of age.
A total of 188 patients (66% males, mean age 63 ± 9
years) were identified from the existing PMI databases at
8 Spanish hospitals. All patients fulfilling inclusion cri-
teria who underwent PMI between January 2015 and
December 2016 were invited to participate. Males were
screened by measuring α-Gal A activity and those with
reduced levels were genetically tested for GLA muta-
tions. All females were tested for mutations in GLA.
Baseline clinical characteristics of the cohort, stratified
by sex, are summarized in Table 1.
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Almost one-third of our cohort presented evidence of
echocardiographic alterations. Left ventricular hyper-
trophy on echocardiogram (≥12 mm) was found in 46%
of patients. ECG signs compatible with AFD, including
prolonged PR interval or left ventricle hypertrophy, were
not infrequently reported (30 and 22%, respectively). Re-
garding other non-cardiac classical findings related to
AFD, 17% of the patients showed some degree of renal
impairment (defined as a glomerular filtration < 50mL/
min/1.73m2), and 3% reported neuropathic disease.
From the 188 patients with conduction problems
undergoing PMI screened for AFD, we failed to find any
patient with the condition. The mean α-Gal A enzyme
activity in males was 3.8 ± 1.7 μmol/L/h, more than
threefold higher than the normal cut-off value
(1.2 μmol/L/h). A total of 75 individuals (11 males and
64 females) were genetically tested for mutations in the
GLA gene. Genetic variants associated with low α-Gal A
enzyme activity that are considered to be polymorphisms
(e.g.,p.D313Y) were present in 1 female but no patient
had a pathogenic mutation.
Reasons for the negative results of the AFD screening
in this population could include relative younger age
and absence of prolonged QRS interval in some of the
patients studied. It has been reported that among AFD
patients, those older and with longer QRS interval (>
110 ms) are at higher risk of requiring antibradycardia
pacing [4]. In our cohort, the mean age was 63 years and
48% of patients exhibited a QRS interval < 110 ms.
In conclusion, although our data suggest that classical
cardiac manifestations attributed to AFD are not rare in
the population requiring PMI, AFD is not a frequent
cause of unexplained conduction problems requiring
PMI. Therefore, it seems that screening efforts should
not be conducted in this patient population.
The appropriate group of patients to whom AFD
screening should be performed in the cardiac setting be-
yond those with unexplained LV hypertrophy ≥15mm
will require further evaluation. Other possible groups of
patients with cardiac disease in whom AFD screening
would need to be evaluated include patients with mild
LVH, those with ECG abnormalities (short PR interval,
high voltages and/or inverted T waves) without overt
LVH, and those with vasospastic angina.
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Table 1 Baseline characteristics of patients with unexplained conduction disorders and who underwent pacemaker implantation
screened for AFD stratified by sex
Total (n = 188) Males (n = 124) Females (n = 64)
Age at pacemaker implantation, years 63 ± 9 64 ± 7 62 ± 8
Medical history of neuropathy, n (%) 5 (3) 4 (3) 1(2)
Medical history of renal impairment, n (%) 24 (13) 20 (16) 4 (6)
Medical history of stroke, n (%) 24 (13) 19 (15) 5 (8)
Family history of SCD, n (%) 14 (7) 8 (7) 6 (9)
Family history of HCM, n (%) 2 (1) 1 (1) 1 (2)
Family history PMI, n (%) 27 (14) 18 (15) 9 (14)
Syncope, n (%) 73 (39) 45 (36) 28 (44)
Serum creatinine (mg/dl) 1.03 ± 0.46 1.08 ± 0.44 0.94 ± 0.49
PR interval, ms 189 ± 0.44 191 ± 57 186 ± 443
QRS interval, ms 116 ± 28 120 ± 27 109 ± 286
LVH in ECG, n (%) 40 (21) 32 (26) 8 (13)
Interventricular septum, mm 12 ± 3 12 ± 3 11 ± 3
LVEF, n (%) 60 ± 10 59 ± 11 63 ± 8
α-Gal activity, μmol/L/h 3.8 ± 1.7 3.9 ± 1.7 3.6 ± 1.6
α-Gal A α-galactosidase A, HCM hypertrophic cardiomyopathy, LVH left ventricular hypertrophy, LVEF left ventricular ejection fraction, PMI pacemaker insertion,
SCD sudden cardiac death
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